Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Alemany

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Journal for Immunotherapy of Cancer|January 5, 2023
Systemic cellular viroimmunotherapy for canine high-grade gliomasAna Cloquell, Isidro Mateo, Stefano Gambera, et al.
Human Gene Therapy|June 23, 2009
Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targetingNeus Bayo-Puxan, Marta Gimenez-Alejandre, Sergio Lavilla-Alonso, et al.
Molecular Therapy. Oncology|September 18, 2024
Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapyAlvaro Morales-Molina, Miguel Angel Rodriguez-Milla, Patricia Garcia-Rodriguez, et al.
International Journal of Molecular Sciences|July 26, 2020
Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral FitnessMartí Farrera-Sal, Jana de Sostoa, Estela Nuñez-Manchón, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2014
Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expressionAlba Rodríguez-García, Marta Giménez-Alejandre, Juan J Rojas, et al.
Molecular Therapy. Oncology|January 29, 2025
KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysisMarc Otero-Mateo, Francesc Estrany, Sabrina Arcas-Márquez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 9, 2016
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic deliveryLuis Alfonso Rojas, Gabriela N Condezo, Rafael Moreno, et al.
Molecular Therapy Oncolytics|February 10, 2022
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibitionJessica Wenthe, Sedigheh Naseri, Ann-Charlotte Hellström, et al.
Human Gene Therapy|August 6, 2014
ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical modelsWenliang Dong, Jan-Willem H van Ginkel, Kam Y Au, et al.
Oncotarget|January 19, 2013
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenograftsAnabel José, Luciano Sobrevals, Juan Miguel Camacho-Sánchez, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|January 5, 2023
Systemic cellular viroimmunotherapy for canine high-grade gliomasAna Cloquell, Isidro Mateo, Stefano Gambera, et al.
Human Gene Therapy|June 23, 2009
Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targetingNeus Bayo-Puxan, Marta Gimenez-Alejandre, Sergio Lavilla-Alonso, et al.
Molecular Therapy. Oncology|September 18, 2024
Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapyAlvaro Morales-Molina, Miguel Angel Rodriguez-Milla, Patricia Garcia-Rodriguez, et al.
International Journal of Molecular Sciences|July 26, 2020
Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral FitnessMartí Farrera-Sal, Jana de Sostoa, Estela Nuñez-Manchón, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2014
Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expressionAlba Rodríguez-García, Marta Giménez-Alejandre, Juan J Rojas, et al.
Molecular Therapy. Oncology|January 29, 2025
KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysisMarc Otero-Mateo, Francesc Estrany, Sabrina Arcas-Márquez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 9, 2016
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic deliveryLuis Alfonso Rojas, Gabriela N Condezo, Rafael Moreno, et al.
Molecular Therapy Oncolytics|February 10, 2022
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibitionJessica Wenthe, Sedigheh Naseri, Ann-Charlotte Hellström, et al.
Human Gene Therapy|August 6, 2014
ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical modelsWenliang Dong, Jan-Willem H van Ginkel, Kam Y Au, et al.
Oncotarget|January 19, 2013
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenograftsAnabel José, Luciano Sobrevals, Juan Miguel Camacho-Sánchez, et al.
Pageof 11